Next-generation sequencing

Get a holistic view of cancer with comprehensive genomic profiling (CGP)

Never miss a detail with enhanced and expanded comprehensive genomic profiling (CGP)

When it comes to cancer, an incomplete picture is an inaccurate picture. Every biomarker reveals unique details that collectively help decipher the genomic landscape of cancer. If you want a holistic view of cancer, comprehensive genomic profiling (CGP) is the way to go. However, emerging targets and evolving guidelines mean adapting assay content can be time-consuming.

Don't risk missing a key cancer biomarker in your research. Unleash the full potential of comprehensive genomic profiling with QIAseq technology. Whether you're looking for a hybrid capture or amplicon-based approach, we've got you covered.

QIAseq panels are for Research Use Only. Not for use in diagnostic procedures.

An end-to-end solution for comprehensive genomic profiling for laboratory research applications

Chris Reynolds
Explore how Myriad Genetics is using QIAseq xHYB CGP Panels

Title: Evaluation of the QIAseq xHYB CGP Panel for a pan-cancer Liquid Biopsy assay: A Proof-of-Concept Study

Speaker: Christopher Reynolds, PhD. Scientist, Myriad Genetics

What is it about? The feasibility and performance of QIAseq xHYB CGP Panel for comprehensive genomic profiling using liquid biopsy

Use QIAseq Pan-cancer Multimodal Panels with just 10 ng total nucleic acid input

The QIAseq Pan-cancer Multimodal Panel uses amplicon-based enrichment to simultaneously profile 605 relevant DNA variants and RNA fusion biomarkers found across multiple cancers, as well as assess tumor mutational burden and microsatellite instability from just 10 ng input. Benefit from a fast, automatable workflow that works with diverse sample types.

QIAseq Multimodal DNA/RNA Library Kit